Abstracts tagged "patient-reported outcome measures and rheumatoid arthritis (RA)"

Abstract Number: 2642 • 2015 ACR/ARHP Annual Meeting
Patient Reported Outcome Assessment of Rheumatoid Arthritis Patients Experience with IV Administered Biologic Therapy
Norman B. Gaylis¹, Joanne Sagliani¹, Danny Tuccitto², Shawn Black³, Kehzen Tang⁴, Raphael Dehoratius^3,5 and Dennis Parenti³, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²AARDS Research, Inc, Aventura, FL, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Patient-reported outcomes (PRO) are used to assess patient related benefit in clinical trials. Rheumatoid arthritis (RA) patients are equally receptive to intravenous (IV) or…
Abstract Number: 2730 • 2015 ACR/ARHP Annual Meeting
Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
Paul Emery¹, Carol L. Gaich², Amy M. DeLozier³, Stephanie de Bono^2,4, Jiajun Liu², Cecile Chang² and Maxime Dougados⁵, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Eli Lilly and Company, Indianapolis, IN, ³Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Cookham, United Kingdom, ⁵Paris-Descartes University, Paris, France
Background/Purpose: Baricitinib (bari) is an oral Janus kinase (JAK) 1 /JAK2 selective inhibitor, representing a potentially effective treatment for patients with moderately to severely active rheumatoid…
Abstract Number: 2299 • 2013 ACR/ARHP Annual Meeting
Disease Activity Scoring: Comparing Patient and Physician Global Assessment Of Disease Activity In Rhumatoid Arthritis Patients Starting a First Biologic Agent
Boulos Haraoui¹, Louis Bessette², Diane Sauvageau¹, Jean Pierre Pelletier³, Jean-Pierre Raynauld¹, Edith Villeneuve¹, Louis Coupal³ and Denis Choquette³, ¹Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: Visual analogue scales (VAS) are routinely used in daily clinical practice and are part of the different composite outcome measures such as the DAS,…
Abstract Number: 2268 • 2013 ACR/ARHP Annual Meeting
Patient-Reported Outcome Measures For Rheumatoid Arthritis: Minimal Important Differences Review
Helen Kitchen¹, Brian Bekker Hansen², Linda Abetz¹, Lise Højbjerre² and Martin Strandberg-Larsen², ¹Endpoint Development & Outcomes Assessment, Adelphi Values Ltd, Cheshire, United Kingdom, ²Health Economics & HTA, Novo Nordisk A/S, Søborg, Denmark
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease, affecting around 1.3 million people in the US. A patient-centred focus is increasingly advocated by healthcare…
Abstract Number: 1031 • 2013 ACR/ARHP Annual Meeting
Health Literacy Predicts Discrepancies Between Traditional Written Rheumatoid Arthritis Patient Assessments and Verbally-Administered Assessments
Joel M. Hirsh¹, Lisa A. Davis^2,3,4, Itziar Quinzanos^5,6,7, Angela Keniston⁸ and Liron Caplan^6,9, ¹Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ²Division of Rheumatology, Univ. of Colorado Sch. of Medicine, Aurora, CO, ³Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁴Denver Veterans Affairs Medical Center, Denver, CO, ⁵Department of Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁶Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, ⁷Department of Medicine, Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁸Department of Medicine, Denver Health and Hospital Authority, Denver, CO, ⁹Department of Medicine, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Patient assessments of disease activity (PtGA) and general health (GH) measured by visual analog scale (VAS) are widely used in rheumatoid arthritis (RA) clinical…
Abstract Number: 431 • 2013 ACR/ARHP Annual Meeting
Prediction Of Week 52 Treatment Response Based On A Week 12 Assessment In Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison Of A Patient-Reported Instrument Versus Physician-Based Disease Activity Assessment
Jeffrey R. Curtis¹, Willem Koetse², Jeymi Tambiah³, Lucian Ionescu⁴ and Yusuf Yazici⁵, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²UCB Pharma, Raleigh, NC, ³UCB Pharma, Smyrna, GA, ⁴UCB Pharma, Brussels, Belgium, ⁵New York University Hospital for Joint Diseases, New York, NY
Background/Purpose: Guidelines support early intervention in rheumatoid arthritis (RA).1,2 The aim was to prospectively test whether outcome assessment at 12 weeks (wks) using a patient-reported…
Abstract Number: 191 • 2013 ACR/ARHP Annual Meeting
Does Specific Joint Involvement In Rheumatoid Arthritis Patients Predict Patient Reported Outcomes? Implications For Clinical Practice
Regan Arendse¹, William G. Bensen², Andrew Chow³, Jude F. Rodrigues⁴, Sanjay Dixit⁵, Dalton E. Sholter⁶, Philip Baer⁷, Milton F. Baker⁸, Denis Choquette⁹, Isabelle Fortin¹⁰, Algis Jovaisas¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, Susan M. Otawa¹⁴, May Shawi¹⁵ and Allen J. Lehman¹⁴, ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ³University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Rheumatology, Windsor, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷Private Practice, Scarborough, ON, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ¹⁰Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ¹¹Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Assessment of functional (dis)ability in rheumatoid arthritis (RA) is subject to patient judgment when appraising their ability to do daily activities. The aim of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].